Which has stronger valuation and earnings, KLRA or EVMN?

Kailera Therapeutics has higher earnings, but lower revenue than Evommune. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kailera Therapeutics N/A N/A N/A N/A N/A Evommune $13M 54.94 -$68.87M -$9.50 N/A

Is KLRA or EVMN more profitable?

Company Net Margins Return on Equity Return on Assets Kailera Therapeutics N/A N/A N/A Evommune N/A N/A N/A

Is EVMN or IRON more profitable?

Evommune's return on equity of 0.00% beat Disc Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Evommune N/A N/A N/A Disc Medicine N/A -36.94% -33.88%

Is EVMN or GPCR more profitable?

Evommune's return on equity of 0.00% beat Structure Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Evommune N/A N/A N/A Structure Therapeutics N/A -24.91% -23.67%

Which has stronger earnings and valuation, EVMN or ALMS?

Evommune has higher earnings, but lower revenue than Alumis. Alumis is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evommune $13M 54.94 -$68.87M -$9.50 N/A Alumis $24.05M 128.02 -$243.32M -$1.98 N/A

Is EVMN or ALMS more profitable?

Evommune has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Evommune's return on equity of 0.00% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets Evommune N/A N/A N/A Alumis -2,825.70% -88.79% -70.72%

Evommune (EVMN) Competitors

$19.83 -0.86 (-4.16%)

Closing price 03:59 PM Eastern

Extended Trading

$19.70 -0.13 (-0.68%)

As of 07:38 PM Eastern

Compare

EVMN vs. KLRA, IRON, ARQT, GPCR, and ALMS

Should you buy Evommune stock or one of its competitors? MarketBeat compares Evommune with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Evommune include Kailera Therapeutics (KLRA), Disc Medicine (IRON), Arcutis Biotherapeutics (ARQT), Structure Therapeutics (GPCR), and Alumis (ALMS). These companies are all part of the "pharmaceutical products" industry.

How does Evommune compare to Kailera Therapeutics?

Kailera Therapeutics (NASDAQ:KLRA) and Evommune (NYSE:EVMN) are both manufacturing companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Kailera Therapeutics currently has a consensus target price of $42.75, suggesting a potential upside of 126.31%. Evommune has a consensus target price of $49.25, suggesting a potential upside of 148.36%. Given Evommune's higher probable upside, analysts clearly believe Evommune is more favorable than Kailera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Evommune	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.00

Kailera Therapeutics has higher earnings, but lower revenue than Evommune.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A
Evommune	$13M	54.94	-$68.87M	-$9.50	N/A

In the previous week, Kailera Therapeutics had 4 more articles in the media than Evommune. MarketBeat recorded 4 mentions for Kailera Therapeutics and 0 mentions for Evommune. Kailera Therapeutics' average media sentiment score of 0.77 beat Evommune's score of 0.00 indicating that Kailera Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Kailera Therapeutics	Positive
Evommune	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
Evommune	N/A	N/A	N/A

Summary

Evommune beats Kailera Therapeutics on 4 of the 6 factors compared between the two stocks.

How does Evommune compare to Disc Medicine?

Evommune (NYSE:EVMN) and Disc Medicine (NASDAQ:IRON) are both pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

Evommune currently has a consensus price target of $49.25, indicating a potential upside of 148.36%. Disc Medicine has a consensus price target of $105.30, indicating a potential upside of 54.88%. Given Evommune's stronger consensus rating and higher possible upside, equities research analysts plainly believe Evommune is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.00
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Evommune's return on equity of 0.00% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	N/A	N/A
Disc Medicine	N/A	-36.94%	-33.88%

In the previous week, Disc Medicine had 11 more articles in the media than Evommune. MarketBeat recorded 11 mentions for Disc Medicine and 0 mentions for Evommune. Disc Medicine's average media sentiment score of 0.39 beat Evommune's score of 0.00 indicating that Disc Medicine is being referred to more favorably in the news media.

Company	Overall Sentiment
Evommune	Neutral
Disc Medicine	Neutral

Evommune has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$13M	54.94	-$68.87M	-$9.50	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A

83.7% of Disc Medicine shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Evommune beats Disc Medicine on 8 of the 14 factors compared between the two stocks.

How does Evommune compare to Arcutis Biotherapeutics?

Evommune (NYSE:EVMN) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

Arcutis Biotherapeutics has higher revenue and earnings than Evommune. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$13M	54.94	-$68.87M	-$9.50	N/A
Arcutis Biotherapeutics	$376.07M	8.11	-$16.14M	-$0.03	N/A

Evommune has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -0.57%. Evommune's return on equity of 0.00% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	N/A	N/A
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%

Evommune presently has a consensus target price of $49.25, indicating a potential upside of 148.36%. Arcutis Biotherapeutics has a consensus target price of $34.00, indicating a potential upside of 39.46%. Given Evommune's stronger consensus rating and higher probable upside, research analysts clearly believe Evommune is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.00
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Arcutis Biotherapeutics had 9 more articles in the media than Evommune. MarketBeat recorded 9 mentions for Arcutis Biotherapeutics and 0 mentions for Evommune. Arcutis Biotherapeutics' average media sentiment score of 1.18 beat Evommune's score of 0.00 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Evommune	Neutral
Arcutis Biotherapeutics	Positive

Summary

Evommune beats Arcutis Biotherapeutics on 9 of the 14 factors compared between the two stocks.

How does Evommune compare to Structure Therapeutics?

Evommune (NYSE:EVMN) and Structure Therapeutics (NASDAQ:GPCR) are both pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

Evommune has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$13M	54.94	-$68.87M	-$9.50	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A

Evommune currently has a consensus price target of $49.25, indicating a potential upside of 148.36%. Structure Therapeutics has a consensus price target of $106.75, indicating a potential upside of 148.66%. Given Structure Therapeutics' higher possible upside, analysts clearly believe Structure Therapeutics is more favorable than Evommune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.00
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	3 Strong Buy rating(s)	2.89

91.8% of Structure Therapeutics shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Evommune's return on equity of 0.00% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	N/A	N/A
Structure Therapeutics	N/A	-24.91%	-23.67%

In the previous week, Structure Therapeutics had 7 more articles in the media than Evommune. MarketBeat recorded 7 mentions for Structure Therapeutics and 0 mentions for Evommune. Structure Therapeutics' average media sentiment score of 0.32 beat Evommune's score of 0.00 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Evommune	Neutral
Structure Therapeutics	Neutral

Summary

Structure Therapeutics beats Evommune on 7 of the 13 factors compared between the two stocks.

How does Evommune compare to Alumis?

Evommune (NYSE:EVMN) and Alumis (NASDAQ:ALMS) are both pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

Evommune has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Evommune's return on equity of 0.00% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	N/A	N/A
Alumis	-2,825.70%	-88.79%	-70.72%

Evommune has higher earnings, but lower revenue than Alumis. Alumis is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$13M	54.94	-$68.87M	-$9.50	N/A
Alumis	$24.05M	128.02	-$243.32M	-$1.98	N/A

In the previous week, Alumis had 2 more articles in the media than Evommune. MarketBeat recorded 2 mentions for Alumis and 0 mentions for Evommune. Alumis' average media sentiment score of 0.94 beat Evommune's score of 0.00 indicating that Alumis is being referred to more favorably in the news media.

Company	Overall Sentiment
Evommune	Neutral
Alumis	Positive

Evommune presently has a consensus target price of $49.25, indicating a potential upside of 148.36%. Alumis has a consensus target price of $40.30, indicating a potential upside of 66.87%. Given Evommune's stronger consensus rating and higher probable upside, research analysts plainly believe Evommune is more favorable than Alumis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.00
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Evommune beats Alumis on 8 of the 13 factors compared between the two stocks.

Get Evommune News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVMN vs. The Competition

Export

Metric	Evommune	Industry	Manufacturing Sector	NYSE Exchange
Market Cap	$714.28M	$2.96B	$4.29B	$23.27B
Dividend Yield	N/A	15.24%	9.53%	4.10%
P/E Ratio	-2.09	13.63	22.14	31.30
Price / Sales	54.94	3,070.07	121.10	12.66
Price / Cash	N/A	26.46	40.76	23.95
Price / Book	3.04	4.37	27.17	4.69
Net Income	-$68.87M	-$40.09M	$118.48M	$1.07B
7 Day Performance	-0.20%	0.82%	0.54%	2.08%
1 Month Performance	-12.57%	0.03%	0.54%	1.84%
1 Year Performance	N/A	15.58%	12.91%	22.17%

Evommune Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVMN Evommune	2.0373 of 5 stars	$19.83 -4.2%	$49.25 +148.4%	N/A	$714.28M	$13M	N/A	45
KLRA Kailera Therapeutics	4.807 of 5 stars	$20.99 -6.2%	$42.75 +103.7%	N/A	$2.72B	N/A	N/A	145
IRON Disc Medicine	2.1321 of 5 stars	$71.11 +1.1%	$105.30 +48.1%	+33.9%	$2.68B	N/A	N/A	30	Analyst Forecast
ARQT Arcutis Biotherapeutics	4.151 of 5 stars	$21.95 +2.8%	$34.00 +54.9%	+79.1%	$2.67B	$376.07M	N/A	150	News Coverage Positive News
GPCR Structure Therapeutics	2.9903 of 5 stars	$39.06 +4.2%	$109.25 +179.7%	+90.6%	$2.67B	N/A	N/A	136	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:EVMN) was last updated on 6/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evommune (EVMN) Competitors

EVMN vs. KLRA, IRON, ARQT, GPCR, and ALMS

How does Evommune compare to Kailera Therapeutics?

Summary

How does Evommune compare to Disc Medicine?

Summary

How does Evommune compare to Arcutis Biotherapeutics?

Summary

How does Evommune compare to Structure Therapeutics?

Summary

How does Evommune compare to Alumis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVMN vs. The Competition

Evommune Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evommune (EVMN) Competitors

EVMN vs. KLRA, IRON, ARQT, GPCR, and ALMS

How does Evommune compare to Kailera Therapeutics?

Do analysts recommend KLRA or EVMN?

Which has stronger valuation and earnings, KLRA or EVMN?

Does the media refer more to KLRA or EVMN?

Is KLRA or EVMN more profitable?

Summary

How does Evommune compare to Disc Medicine?

Do analysts rate EVMN or IRON?

Is EVMN or IRON more profitable?

Does the media refer more to EVMN or IRON?

Which has higher valuation and earnings, EVMN or IRON?

Do institutionals & insiders believe in EVMN or IRON?

Summary

How does Evommune compare to Arcutis Biotherapeutics?

Which has preferable earnings & valuation, EVMN or ARQT?

Is EVMN or ARQT more profitable?

Do analysts rate EVMN or ARQT?

Does the media favor EVMN or ARQT?

Summary

How does Evommune compare to Structure Therapeutics?

Which has preferable earnings & valuation, EVMN or GPCR?

Do analysts prefer EVMN or GPCR?

Do institutionals and insiders have more ownership in EVMN or GPCR?

Is EVMN or GPCR more profitable?

Does the media refer more to EVMN or GPCR?

Summary

How does Evommune compare to Alumis?

Is EVMN or ALMS more profitable?

Which has stronger earnings and valuation, EVMN or ALMS?

Does the media prefer EVMN or ALMS?

Do analysts prefer EVMN or ALMS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVMN vs. The Competition

Evommune Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools